Company news
Anavex Life Sciences Corp. (NASDAQ:AVXL) news
Anavex Life Sciences Corp. news releases on 6ix. Latest, Sep 18, 2026: PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
Press releases & updates
PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
September 18, 2026
Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change
September 17, 2026
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees
September 14, 2026
PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign
September 10, 2026
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
September 8, 2026
Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
September 2, 2026
PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.’s 2026 Annual Meeting
September 1, 2026
Anavex Life Sciences : Amendment to Annual Report (Form 10-K/A)
August 28, 2026
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot
August 25, 2026
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
August 25, 2026
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
August 17, 2026
Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
August 11, 2026
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
August 3, 2026
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
May 22, 2026
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
May 6, 2026
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
April 13, 2026
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026
Anavex Life Sciences Provides Comprehensive Regulatory Update
March 29, 2026
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
March 22, 2026
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
March 20, 2026
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
March 17, 2026
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
March 3, 2026
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
February 25, 2026
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
February 23, 2026
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
February 9, 2026
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
February 3, 2026
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
January 13, 2026
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
January 8, 2026
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
January 6, 2026
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
December 17, 2025
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
December 11, 2025
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 25, 2025
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
November 24, 2025
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
November 18, 2025
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
November 17, 2025
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
November 13, 2025
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
October 28, 2025
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’
October 9, 2025
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
October 1, 2025
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
October 1, 2025
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial
September 29, 2025
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
September 8, 2025
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
September 1, 2025
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
August 25, 2025
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease
August 19, 2025
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
August 11, 2025
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
August 4, 2025
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
July 30, 2025
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
May 13, 2025